Drug Sponsors

Merck Serono, Compugen establish new biomarker company Neviah Genomics

Monday, June 25, 2012 02:52 PM

Merck Serono of Darmstadt, Germany, and Compugen, a therapeutic product discovery company of Tel Aviv, Israel, have established a novel start-up company called Neviah Genomics, focused on the discovery and development of novel biomarkers for the prediction of drug-induced toxicity.

More... »

Teleflex acquires Semprus Biosciences, tech to reduce biological formation on devices

Monday, June 25, 2012 10:43 AM

Teleflex, a global provider of medical devices for critical care and surgery based in Limerick, Penn., has acquired Semprus BioSciences, a Cambridge, Mass.-based biomedical company and spin out from Massachusetts Institute of Technology (MIT), for $30 million.

More... »

West Pharmaceutical signs tech agreement with Amgen

Thursday, June 21, 2012 02:42 PM

West Pharmaceutical Services, a global manufacturer of components and systems for injectable drug delivery, has signed an agreement with Amgen, an independent biotech based in Thousand Oaks, Calif., to evaluate Daikyo Crystal Zenith technologies for drug containment.

More... »

XTL Biopharmaceuticals to acquire Kitov Pharmaceuticals

Thursday, June 21, 2012 12:35 PM

XTL Biopharmaceuticals, an Israel-based biopharmaceutical development company, has agreed to acquire Kitov Pharmaceuticals, an Israel-based company that researches and develops combination drug products with a focus on hypertension and pain induced by osteoarthritis.

More... »

Frazier Healthcare acquires U.S. packaging operations from Catalent

Wednesday, June 20, 2012 03:26 PM

Somerset, N.J.-based Catalent Pharma Solutions has closed the purchase and sale of its U.S. commercial pharmaceutical packaging operations based in Philadelphia, Penn., and Woodstock, Ill., to Frazier Healthcare.

More... »

AstraZeneca, Rigel ink worldwide license for new asthma treatment

Wednesday, June 20, 2012 11:26 AM

Biopharmaceutical companies AstraZeneca and Rigel Pharmaceuticals have signed an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling being investigated as a treatment for moderate to severe chronic asthma. 

More... »

Merck Serono announces final efficiency program for Switzerland

Wednesday, June 20, 2012 10:03 AM

After a long consultation process, Merck Serono, the biopharmaceutical division of Merck, had made its final plan for restructuring its operations in Switzerland, closing its Geneva and Coinsins sites.

More... »

Bioscience industry adds jobs over last decade despite nation’s economic setbacks

Wednesday, June 20, 2012 09:28 AM

The Battelle/BIO State Bioscience Industry Development report signals significant job growth in the bioscience sector over the past decade, indicating the importance of the biosciences as an economic driver for the nation.

More... »

Ambrx, Merck collaborate to develop biologic drug conjugates

Monday, June 18, 2012 03:21 PM

Ambrx, a La Jolla, Calif.-based clinical-stage biopharmaceutical company, has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

More... »

AC Immune, Genentech form second antibody collaboration for Alzheimer's

Monday, June 18, 2012 03:03 PM

Swiss-based biopharmaceutical company AC Immune has entered into a second exclusive worldwide license agreement and research collaboration with Genentech, a member of the Roche Group, for research, development and commercialization of AC Immune's anti-Tau antibodies for the potential treatment of Alzheimer's disease and other neurodegenerative diseases.

More... »